Fluticasoneside effects

Clinical Trial Experience - In controlled clinical trials of twice-daily administration, the total incidence of adverse reactions associated with the use of fluticasone propionate cream, 0.05% was approximately 4%. These adverse reactions were usually mild; self-limiting; and consisted primarily of pruritus, dryness, numbness of fingers, and burning. These events occurred in 2.9%, 1.2%, 1.0%, and 0.6% of patients, respectively. Two clinical studies compared once- to twice-daily administration of fluticasone propionate cream, 0.05% for the treatment of moderate to severe eczema. The local drug-related adverse events for the 491 patients enrolled in both studies are shown in Table 1. In the study enrolling both adult and pediatric patients, the incidence of local adverse events in the 119 pediatric patients ages 1 to 12 years was comparable to the 140 patients ages 13 to 62 years. Fifty-one pediatric patients ages 3 months to 5 years, with moderate to severe eczema, were enrolled in an open-label HPA axis safety study. Fluticasone propionate cream, 0.05% was applied twice daily for 3 to 4 weeks over an arithmetic mean body surface area of 64% (range, 35% to 95%). The mean morning cortisol levels with standard deviations before treatment (prestimulation mean value = 13.76 ± 6.94 mcg/dL, poststimulation mean value = 30.53 ± 7.23 mcg/dL) and at end treatment (prestimulation mean value = 12.32 ± 6.92 mcg/dL, poststimulation mean value = 28.84 ± 7.16 mcg/dL) showed little change. In 2 of 43 (4.7%) patients with end-treatment results, peak cortisol levels following cosyntropin stimulation testing were ≤18 μg/dL, indicating adrenal suppression. Follow-up testing after treatment discontinuation, available for 1 of the 2 subjects, demonstrated a normally responsive HPA axis. Local drug-related adverse events were transient burning, resolving the same day it was reported; transient urticaria, resolving the same day it was reported; erythematous rash; dusky erythema, resolving within 1 month after cessation of fluticasone propionate cream, 0.05%; and telangiectasia, resolving within 3 months after stopping fluticasone propionate cream, 0.05%.

Table 1: Drug-Related Adverse Events-Skin Adverse Events Fluticasone Once Daily (n = 210) Fluticasone Twice Daily (n = 203) Vehicle Twice Daily (n = 78) Skin infection Infected eczema Viral warts Herpes simplex Impetigo Atopic dermatitis Eczema Exacerbation of eczema Erythema Burning Stinging Skin irritation Pruritus Exacerbation of pruritus Folliculitis Blisters Dryness of skin 1 (0.5%) 1 (0.5%) 0 0 1 (0.5%) 1 (0.5%) 1 (0.5%) 4 (1.9%) 0 2 (1.0%) 0 6 (2.9%) 2 (1.0%) 4 (1.9%) 1 (0.5%) 0 3 (1.4%) 0 2 (1.0%) 1 (0.5%) 1 (0.5%) 0 0 0 1 (0.5%) 2 (1.0%) 2 (1.0%) 2 (1.0%) 2 (1.0%) 4. (1.9%) 1 (0.5%) 1 (0.5%) 1 (0.5%) 1 (0.5%) 0 0 0 0 0 0 0 1 (1.3%) 0 2 (2.6%) 1 (1.3%) 0 4 (5.1%) 1 (1.3%) 0 0 0 Table 2: Adverse Events* From Pediatric Open-Label Trial (n=51) Adverse Events Fluticasone Twice Daily Burning Dusky erythema Erythematous rash Facial telangiectasia† Non-facial telangiectasia Urticaria 1 (2.0%) 1 (2.0%) 1 (2.0%) 2 (4.9%) 1 (2.0%) 1 (2.0%) * See text for additional detail. † n=41. Post Marketing Experience - Systemic adverse events with fluticasone propionate cream, 0.05% and fluticasone propionate ointment have included: immunosuppression/Pneumocystis carinii pneumonia/leukopenia/thrombocytopenia; hyperglycemia/glycosuria; Cushing’s syndrome; generalized body edema/blurred vision; and acute urticarial reaction (edema, urticaria, pruritus, and throat swelling). The following localized adverse reactions have been reported during post approval use of fluticasone propionate cream, 0.05%: skin discoloration, erythema, irritation, edema/swelling, atrophy, contusion, dermatitis, pain, sepsis, hemorrhage, acneiform eruptions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.